Josh Hardy: An unanswered call Decision tree for compassionate use The principles guiding decisions about compassionate access should be the same regardless of the details of the individual request, and no matter …

Drug price changes loom in China Out-of-Pocket Impact Example of out-of-pocket impact on pricing for statins before and after China moves to standard reimbursement levels for branded mature drugs from MNCs and …

Facing up to China's vicissitudes Ensuring corruption-free trials Companies conducting clinical trials in China now face an additional layer of scrutiny at the hospital level that may further delay drug approvals.…

Facing up to China's vicissitudes Want to get into China faster? Dan Zhang, CEO of CRO Fountain Medical Development Ltd., suggests four steps multinational companies can take to get their approved products on the …

Facing up to China's vicissitudes China Registration Process For Imported Small Molecules The new CFDA policy interpretation on multiregional clinical trials (MRCTs) could add two to four years to regulatory …

Patient factors Bleeding disorder pipeline At least 19 compounds are in Phase II or Phase III testing for hemophilia and other bleeding disorders. The analysis does not include biosimilars. Source: BCIQ: BioCentury …